 Protara Therapeutics Inc NASDAQ: TARA is trading higher Tuesday after the company announced FDA clearance of the Investigational New Drug application for TARA-002 for the treatment of non-muscle invasive bladder cancer. Protara Therapeutics expects to begin a Phase 1 clinical trial of TARA-002 in adults with high-grade non-muscle invasive bladder cancer by the end of 2021. 